For investors with $10,000 ready to put to work, the ASX offers plenty of quality options.
But which ones are buys right now?
Let's take a look at three ASX shares that could be smart places to invest this month according to analysts. They are as follows:
Cochlear Ltd (ASX: COH)
The first ASX share to look at is Cochlear. It is a global leader in hearing implants and related technologies. Its brand strength, history of innovation, and relationships with healthcare professionals give it a powerful competitive moat.
The company benefits from clear demographic tailwinds. As populations age and awareness of hearing health increases, demand for implants and related services is expected to rise steadily. On top of that, Cochlear's large installed base of patients provides recurring revenue from upgrades and servicing, supporting consistent cash flows.
UBS is bullish on Cochlear and has a buy rating and $350.00 price target on its shares.
DroneShield Ltd (ASX: DRO)
DroneShield is operating in a sector with significant growth potential. This ASX share develops and supplies counter-drone technology used by defence and security organisations worldwide. With the growing adoption of drones across industries, the need for effective countermeasures is becoming more pressing.
DroneShield has already secured contracts with governments and defence groups, building credibility in a highly specialised market. While it remains higher risk due to its size and reliance on winning contracts, its potential rewards are substantial if it continues to execute on its strategy. And with defence trends certainly in its favour at present, it would be hard to bet against this happening.
Bell Potter is a big fan of this ASX share and has a buy rating and $3.70 price target on its shares.
ResMed Inc. (ASX: RMD)
A third ASX share to look at according to analysts is ResMed. IT is another global healthcare leader, focused on treating sleep apnoea and other chronic respiratory conditions.
With over a billion people worldwide estimated to be affected by sleep disorders, ResMed has an enormous addressable market.
The company has also expanded into digital health solutions, integrating cloud platforms and wearables to provide better patient outcomes and build stickier customer relationships. In addition, its strong operating leverage means profits have been growing faster than revenues in recent times, which highlights the scalability of its business.
Macquarie is positive on ResMed's outlook and has an overweight rating and $48.60 price target on its shares.
